Ocular Therapeutix (OCUL) Enterprise Value (2013 - 2026)

Ocular Therapeutix's Enterprise Value history runs 14 years deep, the most recent figure standing at -$666.7 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 90.66% year-over-year to -$666.7 million; the TTM figure through Mar 2026 stood at -$666.7 million (down 90.66% YoY), while the FY2025 annual figure was -$737.1 million, down 87.98% from the prior year.
• Enterprise Value was -$666.7 million for Q1 2026 at Ocular Therapeutix, up from -$737.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$66.6 million in Q2 2023 to a low of -$737.1 million in Q4 2025.
• Historically, Enterprise Value has averaged -$306.3 million across 5 years, with a median of -$344.8 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value jumped 50.49% in 2023, then slumped 590.16% in 2024.
• A 5-year view of Enterprise Value shows it stood at -$102.3 million in 2022, then plunged by 91.55% to -$196.0 million in 2023, then tumbled by 100.1% to -$392.1 million in 2024, then sank by 87.98% to -$737.1 million in 2025, then increased by 9.55% to -$666.7 million in 2026.
• The last three Enterprise Value figures came in at -$666.7 million (Q1 2026), -$737.1 million (Q4 2025), and -$344.8 million (Q3 2025), per Business Quant data.